Want to see MLYS full AI Analyst Report?
MLYS Stock Chart & Stats
$26.34
-$0.29(-1.07%)
At close: 4:00 PM EDT
$26.34
-$0.29(-1.07%)
Day’s Range― - ―
52-Week Range$20.12 - $47.65
Previous CloseN/A
Volume648.86K
Average Volume (3M)1.38M
Market Cap
$1.87B
Enterprise Value$1.72B
Total Cash (Recent Filing)$661.41M
Total Debt (Recent Filing)$97.62M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Nov 16, 2026EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.24
Shares Outstanding88,406,880
10 Day Avg. Volume1,262,722
30 Day Avg. Volume1,384,794
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)3.80
Price to Sales (P/S)0.00
P/FCF Ratio-17.24
Enterprise Value/Market Cap0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-82.01K
Enterprise Value/Ebitda-4.93
Forecast
1Y Price Target
$47.86Price Target Upside81.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-4.48
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyMeaningful and durable blood-pressure reductions, together with improved albuminuria in relevant patients, support lorundrostat’s potential clinical differentiation. The broader biomarker evidence may also strengthen its positioning across hypertension and cardiorenal indications if regulatory and commercial milestones are achieved.
Regulatory And Launch ReadinessAn NDA under review and a defined PDUFA date provide a clear regulatory pathway, while established commercial infrastructure can reduce execution time if approval occurs. Early sales planning and payer engagement may support a more coordinated launch and improve access preparation.
Funding RunwaySubstantial liquidity, supplemented by the equity offering and committed term loan, gives Mineralys resources to fund late-stage development and planned commercialization. A runway extending into 2028 provides time to execute regulatory, market-access and launch activities without immediate financing dependence.
Bears Say
Pre-Revenue Losses And Cash BurnMineralys has no operating revenue to offset research, development and commercial preparation costs, leaving earnings dependent on external funding. Widening losses and substantial negative cash flow could pressure financial flexibility and make sustained execution dependent on successful financing or commercialization.
Debt And Milestone ObligationsNew secured debt introduces recurring interest and amortization requirements before the business has generated product revenue. Additional milestone exposure could further consume future cash, reducing flexibility for development, launch investment and other capital-allocation priorities.
Reimbursement And Competitive UncertaintyUnresolved pricing and reimbursement arrangements could slow or limit patient access after approval, particularly if Medicare coverage initially depends on exceptions. An earlier competing launch may also pressure market share and rebate economics, making commercial uptake and revenue conversion less predictable.
Mineralys Therapeutics, Inc. News
MLYS FAQ
What was Mineralys Therapeutics, Inc.’s price range in the past 12 months?
Mineralys Therapeutics, Inc. lowest stock price was $20.12 and its highest was $47.65 in the past 12 months.
What is Mineralys Therapeutics, Inc.’s market cap?
Mineralys Therapeutics, Inc.’s market cap is $1.87B.
When is Mineralys Therapeutics, Inc.’s upcoming earnings report date?
Mineralys Therapeutics, Inc.’s upcoming earnings report date is Nov 16, 2026 which is in 19 days.
How were Mineralys Therapeutics, Inc.’s earnings last quarter?
Mineralys Therapeutics, Inc. released its earnings results on Aug 11, 2026. The company reported -$2.85 earnings per share for the quarter, missing the consensus estimate of -$0.549 by -$2.301.
Is Mineralys Therapeutics, Inc. overvalued?
According to Wall Street analysts Mineralys Therapeutics, Inc.’s price is currently Undervalued.
Does Mineralys Therapeutics, Inc. pay dividends?
Mineralys Therapeutics, Inc. does not currently pay dividends.
What is Mineralys Therapeutics, Inc.’s EPS estimate?
Mineralys Therapeutics, Inc.’s EPS estimate is -0.56.
How many shares outstanding does Mineralys Therapeutics, Inc. have?
Mineralys Therapeutics, Inc. has 88,406,880 shares outstanding.
What happened to Mineralys Therapeutics, Inc.’s price movement after its last earnings report?
Mineralys Therapeutics, Inc. reported an EPS of -$2.85 in its last earnings report, missing expectations of -$0.549. Following the earnings report the stock price went down -1.025%.
Which hedge fund is a major shareholder of Mineralys Therapeutics, Inc.?
Currently, no hedge funds are holding shares in MLYS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mineralys Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$47.86 (81.69% Upside)
$47.86 (81.69% Upside)
Blogger Sentiment
Bullish
MLYS Sentiment 67%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 4.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.90%
12-Months-Change
Fundamentals
Return on Equity
-57.97%
Trailing 12-Months
Asset Growth
98.93%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
MLYS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong clinical data, regulatory progress toward a December 22, 2026 PDUFA, significant commercial launch preparation, and strategic actions (royalty repurchase and financing) intended to enhance long-term value and provide runway into 2028. These positive, strategic developments were tempered by materially higher near‑term expenses and a widened quarterly net loss driven largely by a one-time $200 million upfront payment and increased commercial hiring and professional fees. Management framed the elevated costs as deliberate investments to support launch readiness and future value capture.View all MLYS earnings summariesMLYS Stock 12 Month Forecast
Average Price Target
$47.86
▲(81.69% Upside)
Technical Analysis
Innoviva
―
Ultragenyx Pharmaceutical
―
Ardelyx
―
Structure Therapeutics, Inc. Sponsored ADR
―
Kailera Therapeutics, Inc.
―
Ownership Overview
25.20% Insiders
17.03% Mutual Funds
2.00% Other Institutional Investors
44.57% Public Companies and
Individual Investors